Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMC114/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1 infection
2005-002486-36Phase 3Completed
- Sponsor
- Tibotec
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of darunavir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Tibotec. Primary endpoint: Primary virologic non-inferiority at 48 weeks. Started Oct 2005; status: completed.
02
Drugs
darunavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-002486-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002486-36.